9ASG image
Deposition Date 2024-02-25
Release Date 2024-12-11
Last Version Date 2025-07-09
Entry Detail
PDB ID:
9ASG
Keywords:
Title:
Crystal structure of HLA-A*03:01 in complex with a mutant PIK3CA peptide analogue (Trp-6 Bta)
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.03 Å
R-Value Free:
0.23
R-Value Work:
0.20
R-Value Observed:
0.20
Space Group:
P 6 2 2
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:HLA class I histocompatibility antigen, A alpha chain
Gene (Uniprot):HLA-A
Chain IDs:A
Chain Length:274
Number of Molecules:1
Biological Source:Homo sapiens
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Beta-2-microglobulin
Gene (Uniprot):B2M
Chain IDs:B
Chain Length:100
Number of Molecules:1
Biological Source:Homo sapiens
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
Gene (Uniprot):PIK3CA
Mutagens:H2L, W6Bta
Chain IDs:C
Chain Length:9
Number of Molecules:1
Biological Source:Homo sapiens
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
4OG C TRP modified residue
Ligand Molecules
Primary Citation
Dynamic allostery in the peptide/MHC complex enables TCR neoantigen selectivity.
Nat Commun 16 849 849 (2025)
PMID: 39833157 DOI: 10.1038/s41467-025-56004-8

Abstact

The inherent antigen cross-reactivity of the T cell receptor (TCR) is balanced by high specificity. Surprisingly, TCR specificity often manifests in ways not easily interpreted from static structures. Here we show that TCR discrimination between an HLA-A*03:01 (HLA-A3)-restricted public neoantigen and its wild-type (WT) counterpart emerges from distinct motions within the HLA-A3 peptide binding groove that vary with the identity of the peptide's first primary anchor. These motions create a dynamic gate that, in the presence of the WT peptide, impedes a large conformational change required for TCR binding. The neoantigen is insusceptible to this limiting dynamic, and, with the gate open, upon TCR binding the central tryptophan can transit underneath the peptide backbone to the opposing side of the HLA-A3 peptide binding groove. Our findings thus reveal a novel mechanism driving TCR specificity for a cancer neoantigen that is rooted in the dynamic and allosteric nature of peptide/MHC-I binding grooves, with implications for resolving long-standing and often confounding questions about T cell specificity.

Legend

Protein

Chemical

Disease

Primary Citation of related structures